Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
08:59am, Tuesday, 24'th Feb 2026
This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.
First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review
02:27pm, Thursday, 19'th Feb 2026
First Eagle Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of 1.71% in fourth quarter 2025. Small Cap Opportunity Fund A Shares (without sales charge*) posted a return of
Principal Financial Group Inc. Purchases 21,002 Shares of AxoGen, Inc. $AXGN
03:32am, Thursday, 19'th Feb 2026
Principal Financial Group Inc. raised its holdings in AxoGen, Inc. (NASDAQ: AXGN) by 69.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
07:00am, Tuesday, 17'th Feb 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
07:00am, Tuesday, 10'th Feb 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
Wasatch Micro Cap Fund Q4 2025 Performance Review
08:35am, Wednesday, 04'th Feb 2026
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and p
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
11:18pm, Wednesday, 21'st Jan 2026
ALACHUA, Fla. and TAMPA, Fla.
Axogen Announces Proposed Public Offering of Common Stock
04:09pm, Wednesday, 21'st Jan 2026
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:25pm, Thursday, 15'th Jan 2026
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen CEO Axed 25,000 Shares From His Direct Holdings
07:07am, Wednesday, 14'th Jan 2026
Axogen's CEO sold 25,000 shares directly for $750,000 on Dec. 10, 2025. The sale represented 28.24% of the CEO's direct holdings prior to the transaction, reducing direct ownership to 63,537 shares (a
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
07:00am, Monday, 12'th Jan 2026
ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera
Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN
03:26am, Saturday, 20'th Dec 2025
Assenagon Asset Management S.A. grew its stake in shares of AxoGen, Inc. (NASDAQ: AXGN) by 26.0% during the third quarter, according to the company in its most recent disclosure with the Securities an
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
08:01pm, Wednesday, 03'rd Dec 2025
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of periph
FDA approves Axogen's nerve repair graft
06:53pm, Wednesday, 03'rd Dec 2025
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen
12:33pm, Monday, 01'st Dec 2025
Axogen, Inc. delivered strong Q3 '25 results, with revenue up 23.7% and a return to profitability, fueling bullish momentum. Surgeon adoption is accelerating ahead of the December 5th FDA decision on
